Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
disruptive behavioral symptoms in patients with moderate- severe dementia with Lewy bodies. Findings: Improvement in symptoms seen by clinician and caregivers supported by changes on respective scales. Message: Preliminary positive evidence suggesting that low dose gabapentin can be used for treatment of patients with dementia with Lewy bodies. The authors describe the use of gabapentin in the treatment of 4 outpatients with dementia-associated agitation. On the basis of clinical case reports and the Overt Agitation Severity Scale, all 4 patients had reduced agitation with gabapentin. Three of 4 patients were successfully titrated to a full dose of 2,400mg/day. These findings suggest a possible role for gabapentin in the behavioral Gabapentin, an anticonvulsant that appears to have a unique mechanism of antiseizure activity, is another drug that has been considered for the treatment of agitation in dementia. One drug in that last class, gabapentin, accounted for one-third of all the days of prescription supply that the patients in the study received during the study period. While gabapentin is approved to treat epilepsy, few of these older adults had a seizure disorder. The results of this study in patients with probable Alzheimer's disease with behavioural alterations and serious comorbidities indicate that gabapentin provides significant and sustained efficacy in terms of behaviour, with associated reductions in caregiver burden. A systematic review analyzing 24 relevant articles found that the use of gabapentinoid agents significantly decreased BPSD in patients with Alzheimer’s disease, suggesting a possible benefit. However, 15 papers were original case series/case reports, and the remaining 9 papers were solely reviews. Gabapentin use was significantly associated with decline in cognitive and functional status among older adults with initially normal cognition. Further studies are needed to examine the association. However, the relation between gabapentin initiation and longer-term neurocognitive changes is not well understood. A retrospective cohort study was conducted using the National Alzheimer’s Coordinating Center Uniform Data Set (2005-March 2023). Drug interaction, which is very rare with these medications, is a major problem in the elderly increasing the adverse effects. For these reasons, gabapentin has recently been included in treatment regimens for agitation in dementia patients [1], [11]. Data regarding the use of gabapentin in AD has been accumulating since 1997. Applying the inclusion and exclusion criteria yielded 201,492 patients for the study: 25,373 in the dementia cohort and 174,930 in the non-dementia cohort. Post 1:1 matching, and after excluding recent gabapentin use (within three months of the index date), the study comprised 22,769 individuals in the dementia cohort and 22,644 in the non-dementia Depiction of study design comparing gabapentin initiators and nonusers. 2.3 Gabapentin use determination. Medication use in the UDS is operationalized via an interview that asks participants to report all medications, including prescriptions and over-the-counter medications, they have used in the 2 weeks preceding their annual study visit. We describe a case where gabapentin was used to treat a patient with mixed Alzheimer's/vascular dementia presenting with severe aggression requiring hospitalization. The case is followed by a systematic review of current literature of the use of these drugs in aggression in patients with dementia. Of them, 34,467 gabapentin- or pregabalin-exposure and 172,335 non-exposure patients were used for analysis. The mean follow-up day (±standard deviation) after the index date was 1724.76 (±1282.32) and 1881.45 (±1303.69) in the exposure and non-exposure groups, respectively; the incidence rates of dementia were 980.60 and 605.48 per 100,000 We would like to show you a description here but the site won’t allow us. Preliminary low-grade evidence based on case series and case reviews suggests possible benefit of gabapentin and pregabalin in patients with BPSD in Alzheimer's disease. These benefits cannot be confirmed until well-powered randomized controlled trials are undertaken. Since gabapentin is also prescribed to treat behavioral and psychological symptoms of dementia (BPSD) 19, gabapentin could be widely prescribed in patients with dementia. However, a recent paper addressed that there is a possibility of an association between gabapentin and cognitive decline 20. Several case reports describe using gabapentin, an anti-epileptic and FDA-approved treatment for neuropathic pain, as an off-label treatment for BPSD. BPSD in some patients may be driven by unreported neuropathic pain, which gabapentin can treat effectively. We present the case of a patient with incipient vascular dementia accompanied by nocturnal agitation, which was successfully treated with gabapentin. Gabapentin appears to be useful and well-tolerated in this indication. A chi-square test analyzed categorical variables, while the Student's t-test assessed continuous variables when comparing dementia and non-dementia groups, including differences in the distribution of gabapentin use, age, sex, hypertension, hyperlipidemia, chronic liver disease, chronic kidney disease diabetes, malignancy, chronic obstructive Gabapentin has been administered to several geriatric patients with bipolar disorder and patients with dementia. It has also been reported to be successful in the treatment of a 13-year-old boy with behavioural dyscontrol, a finding that suggested a possible role for gabapentin in the treatment of other behavioural disorders.
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |